Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-8025 in Primary Biliary Cholangitis with Inadequate UDCA Response
2015-002698-39Phase 2Completed
- Sponsor
- CymaBay Therapeutics
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seladelpar in primary biliary cholangitis (PBC) (3 arms), sponsored by CymaBay Therapeutics. Primary endpoint: Change in alkaline phosphatase levels. Started Sep 2015; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2015-002698-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002698-39.